CLAIMS

1. Use of an O-antigen in the manufacture of a medicament for treating a bacterial infection, wherein the medicament to be administered mobilises transitional premonocytes (TpMos) from a bone marrow into a peripheral blood of a subject and wherein the O-antigen comprises the structure DGlc-(α1-4)-DGal-(α1-3)-DGlcNAc.

2. The use of claim 1, wherein the bacterial infection is bacterial sepsis.

3. The use of claims 1 or 2, wherein the O-antigen is an O-antigen from *E. coli* O18 serotype or O111 serotype.

4. The use of claim 3, wherein the *E. coli* O18 serotype is *E. coli* UTI89 strain.

5. The use of any one of claims 1 to 4, wherein the medicament is used as an adjunct treatment.

6. The use of any one of claims 1 to 5, wherein the amount of O-antigen to be administered is between 40ng and 400ng.

7. A pharmaceutical composition comprising (a) a therapeutically effective amount of an O-antigen for mobilizing transitional premonocytes (TpMos) from bone marrow into peripheral blood of a subject, wherein the O-antigen comprises the structure DGlc-(α1-4)-DGal(α1-3)-DGlcNAc; and (b) one or more pharmaceutically acceptable carriers and/or diluents.

8. The pharmaceutical composition of claim 7, wherein the O-antigen is an O-antigen from *E. coli*.

9. The pharmaceutical composition of claims 7 or 8, wherein the O-antigen is an O-antigen from *E. coli* O18 serotype or O111 serotype.

10. The pharmaceutical composition of claim 9, wherein the *E. coli* O18 serotype is *E. coli* UTI89 strain.